Could high serum neopterin levels serve as a biomarker for patients diagnosed with rosacea, specifically the papulopustular rosacea subtype?
OPEN MEDICINE, cilt.21, sa.1, 2026 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 21 Sayı: 1
- Basım Tarihi: 2026
- Doi Numarası: 10.1515/med-2026-1435
- Dergi Adı: OPEN MEDICINE
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, Directory of Open Access Journals, Academic Search Ultimate (EBSCO), Biomedical Reference Collection: Corporate Edition (EBSCO), Health Research Premium Collection (ProQuest), Pharma Collection (ProQuest)
- Gazi Üniversitesi Adresli: Evet
Özet
Objectives: This study aimed to compare serum neopterin and other inflammatory marker levels between patients with rosacea and healthy controls and to investigate the potential role of neopterin in disease diagnosis and severity assessment. Methods: Forty drug-naive patients clinically diagnosed with papulopustular rosacea and forty healthy controls were included. The serum levels of neopterin and other inflammatory markers were measured. The Investigator's Global Assessment (IGA) score was used to assess the patient's disease severity. Results: Serum neopterin, TNF-alpha, IFN-gamma, and CRP levels were significantly higher in patients with papulopustular rosacea than in controls. A positive correlation was found between neopterin, TNF-alpha, IFN-gamma, and IGA scores (r=0.498, 0.523, and 0.432, respectively). ROC curve analysis demonstrated good diagnostic performance for IFN-gamma (AUC=0.821), TNF-alpha (AUC=0.780), and neopterin (AUC=0.747). Conclusions: New biochemical markers are needed to assess rosacea severity. Neopterin may be a potential biomarker for rosacea.